How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

49,173 results for

Obesity Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Influence of obesity on the efficacy of antithrombotic therapy: a systematic review and meta-analysis

Influence of obesity on the efficacy of antithrombotic therapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we

2021 PROSPERO

162. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents Full Text available with Trip Pro

Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents Obesity and its related metabolic disorders are serious health problems worldwide, and lead to various health-related complications, including cancer. Among human cancers, hepatocellular carcinoma (HCC) is one of the most common malignancies affected by obesity. Therefore, obesity and its related disorders might be a key target for the prevention of HCC. Recently, new research indicates (...) , a pharmaceutical agent, reduced the incidence of HCC in obese and diabetic mice, and was also associated with improvements in insulin resistance and chronic inflammation. In this article, we review the detailed molecular mechanisms that link obesity to the development of HCC in obese individuals. We also summarize recent evidence from experimental and clinical studies using either nutraceutical or pharmaceutical agents, and suggest that nutraceutical and pharmaceutical approaches targeting metabolic

2016 World Journal of Gastroenterology

163. Gender-related issues in the pharmacology of new anti-obesity drugs. (Abstract)

Gender-related issues in the pharmacology of new anti-obesity drugs. Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease. To achieve satisfactory anti-obesity goals, the use of these new medicines should be optimized and tailored to specific patient subpopulations also by applying dose adjustments if needed (...) . In the present review, we posit that gender could be among the factors influencing the activity of the new obesity drugs both because of pharmacokinetic and pharmacodynamic factors. Although evidence from premarketing clinical studies suggested that no dose adjustment by gender is necessary for any of these new medicines, these studies were not specifically designed to identify gender-related differences. This observation, together with the strong theoretical background supporting the hypothesis of a gender

2018 Obesity Reviews

164. Effects of antiobesity drugs on bone health of obese patients-a systematic review and Meta-analysis

Effects of antiobesity drugs on bone health of obese patients-a systematic review and Meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) . review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract

2020 PROSPERO

165. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue Full Text available with Trip Pro

Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue Metabolic syndrome can be defined as a state of disturbed metabolic homeostasis characterized by visceral obesity, atherogenic dyslipidemia, arterial hypertension, and insulin resistance. The growing prevalence of metabolic syndrome will certainly contribute to the burden of cardiovascular disease. Obesity and dyslipidemia are main features of metabolic syndrome, and both can present with adipose tissue dysfunction (...) , involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue. Specifically, we explored how these drugs can modulate the complex pathways involved in metabolism, inflammation, atherogenesis, insulin sensitivity

2018 International journal of endocrinology

166. Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. Full Text available with Trip Pro

Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. To assess appropriate pantoprazole dosing for obese children, we conducted a prospective pharmacokinetics (PK) investigation of pantoprazole in obese children, a patient population that is traditionally excluded from clinical trials.A total of 41 obese children (6-17 years of age), genotyped for CYP2C19 variants *2, *3, *4, and *17, received a single oral dose of pantoprazole, ~1.2 (...)  mg/kg lean body weight (LBW), with LBW calculated via a validated formula. Ten post-dose pantoprazole plasma concentrations were measured, and PK variables generated via noncompartmental methods (WinNonlin). Linear and nonlinear regression analyses and analyses of variance were used to explore obesity, age, and CYP2C19 genotype contribution to pantoprazole PK. PK variables of interest were compared with historic nonobese peers treated with pantoprazole.Independent of genotype, when normalized

2018 Journal of Pediatrics

167. The polyherbal drug GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits hepatic steatosis and fibroinflammtion in high-fat diet-induced obese mice. (Abstract)

The polyherbal drug GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits hepatic steatosis and fibroinflammtion in high-fat diet-induced obese mice. The herbal composition Gyeongshingangjeehwan 18 (GGEx18), composed of Rheum palmatum L. (Polygonaceae), Laminaria japonica Aresch (Laminariaceae), and Ephedra sinica Stapf (Ephedraceae), is used as an antiobesity drug in Korean clinics. The constituents of GGEx18 have traditionally been reported to inhibit obesity and related (...) -smooth muscle actin-positive cells, and collagen levels induced by an HFD. Consistent with the histological data, the hepatic expression of lipogenesis-, inflammation-, and fibrosis-related genes was lower, while hepatic fatty acid β-oxidation-related gene expression was higher, in mice receiving GGEx18 compared to mice fed only the HFD.These results indicate that GGEx18 attenuates visceral obesity and NAFLD, in part by altering the expression of genes involved in hepatic steatosis

2018 Journal of Ethnopharmacology

168. Perioperative considerations for airway management and drug dosing in obese children. (Abstract)

Perioperative considerations for airway management and drug dosing in obese children. Childhood obesity, a phenomenon that is increasing globally, holds substantial relevance for pediatric anesthesia. In particular, understanding the nuances of airway management and drug dosing in obese children can be daunting.Respiratory adverse events and challenges in managing the airway may be anticipated. In addition, drug-dosing strategies for the obese child are complex and poorly understood although (...) recent advances have clarified the optimal dosing for anesthetics in these children.Theoretical knowledge, practical skills, meticulous risk stratification and optimal drug regimens are crucial to ensure the safe conduct of anesthesia for obese children.

2018 Current Opinion in Anaesthesiology

169. European Academy of Neurology guideline on the management of medication-overuse headache

- usual frequency during the initial withdrawal period without the fear of causing rebound MOH. The drugs proposed for the treatment of headache dur- ing withdrawal as a bridging therapy are those rec- ommended for the acute migraine attack, e.g. diphenhydramine [93], dihydroergotamine [94], anti- dopaminergic drugs (chlorpromazine, prochlorper- azine, metoclopramide, droperidol) [95-98], valproic acid [99], ketorolac [10], magnesium [11] or corticos- teroids [12,103]. Many medications have been (...) studied as short-term therapy in a limited number of case series. Pascual and Berciano [14] concluded that naproxen, a long- acting non-steroidal anti-in?ammatory drug, was ben- e?cial as a rescue medication for patients with MOH. Tizanidine has been studied as an adjunct to a long- acting non-steroidal anti-in?ammatory drug and was shown to be helpful [15]. Patients overusing opiates, barbiturates and tranquilizers may require long-acting opioids, phenobarbital and clonidine as a transition during

2020 European Academy of Neurology

170. Extremely medically vulnerable groups with respect to COVID-19

that weaken the immune system, such as leukaemia or lymphoma that is currently undergoing cytostatic treatment (not maintenance therapy) ? Medication which significantly weakens the immune system (e.g. high-dosage cortisone therapy). Rapid review of public health guidance on protective measures for vulnerable groups Health Information and Quality Authority Page 19 of 61 Other factors that generally impair lung functioning and may increase the health risk of a coronavirus infection include morbid obesity (...) immunosuppression drugs. ? People with severe respiratory conditions including all cystic fibrosis, severe asthma and severe chronic obstructive pulmonary (COPD). ? People with rare diseases that significantly increase the risk of infections (such as severe combined immunodeficiency (SCID), homozygous sickle cell). ? People on immunosuppression therapies sufficient to significantly increase risk of infection. ? Women who are pregnant with significant heart disease, congenital or acquired. ? Other people have

2020 Health Information and Quality Authority

171. Medical scientists and philosophers worldwide appeal to EBM to expand the notion of ‘evidence’ Full Text available with Trip Pro

Medical scientists and philosophers worldwide appeal to EBM to expand the notion of ‘evidence’ Medical scientists and philosophers worldwide appeal to EBM to expand the notion of ‘evidence’ | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Medical scientists and philosophers worldwide appeal to EBM to expand the notion of ‘evidence’ Article Text EBM opinion and debate Medical scientists and philosophers worldwide appeal to EBM to expand the notion of ‘evidence’ Free Rani Lill Anjum , Samantha Copeland , Elena Rocca Statistics from Altmetric.com The rapid dominance of evidence-based medicine has sparked a philosophical debate concerning

2020 Evidence-Based Medicine

172. A precision medicine approach to develop and internally validate optimal exercise and weight loss treatments for overweight and obese adults with knee osteoarthritis. (Abstract)

A precision medicine approach to develop and internally validate optimal exercise and weight loss treatments for overweight and obese adults with knee osteoarthritis. Apply a precision medicine approach to determine the optimal treatment regime for participants in an exercise (E), dietary weight loss (D), and D+E trial for knee osteoarthritis (KOA) that would have maximized their expected outcomes.Using data from 343 participants of the Intensive Diet and Exercise for Arthritis (IDEA) trial, we (...) with 9.8 kg if all received D+E (p = 0.01).The precision medicine models supported the overall findings from IDEA that the D+E intervention was optimal for most participants, but there was evidence that a subgroup of participants would likely benefit more from diet alone for two outcomes.This article is protected by copyright. All rights reserved.

2020 Arthritis care & research

173. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition Full Text available with Trip Pro

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition Guidelines for the Provision and Assessment of Nutrition Sup... : Pediatric Critical Care Medicine 1 mo and < 18 yr) critically ill patient expected to require a length of stay greater than 2 or 3 days in a PICU admitting medical, surgical, and cardiac patients. In total, 2,032 citations were (...) Medicine, to describe best practices in nutrition therapy in critically ill children. The target of these guidelines is intended to be the pediatric (> 1 mo and < 18 yr) critically ill patient expected to require a length of stay greater than 2 or 3 days in a PICU admitting medical, surgical, and cardiac patients. In total, 2,032 citations were scanned for relevance. The PubMed/Medline search resulted in 960 citations for clinical trials and 925 citations for cohort studies. The EMBASE search

2017 Society of Critical Care Medicine

174. A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial. (Abstract)

A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial. 29470327 2018 02 22 1873-233X 131 3 2018 Mar Obstetrics and gynecology Obstet Gynecol A Medically Supervised Pregnancy Exercise Intervention in Obese Women: A Randomized Controlled Trial. 599 10.1097/AOG.0000000000002505 Cambos Sophie S Endocrinology-Nutrition Department, CHU Bordeaux, Hospital Haut-Leveque, Pessac, France. Rigalleau Vincent V Blanco Laurence L eng Journal Article United States

2018 Obstetrics and Gynecology Controlled trial quality: predicted high

175. Effects of medical trainees' weight-loss history on perceptions of patients with obesity. (Abstract)

Effects of medical trainees' weight-loss history on perceptions of patients with obesity. Medical professionals often express weight-biased attitudes. Prior research suggests that people who overcome a challenge are critical of individuals who struggle to overcome the same challenge. Thus, medical trainees who have successfully achieved and maintained weight loss may express greater weight bias and more critical attitudes toward patients with obesity who fail to overcome these challenges.This (...) study was designed to determine the effects of medical trainees' weight-loss history on weight-biased attitudes and responses to patients with varying weight-loss outcomes.An online survey was completed by 219 medical students and internal medicine residents. Participants' weight-biased attitudes were assessed before they were randomly assigned to read one of three patient vignettes in which the patient lost no weight, lost/regained weight, or lost/maintained weight. Independent measures included

2018 Medical education Controlled trial quality: uncertain

176. Medication use for the treatment of diabetes in obese individuals. Full Text available with Trip Pro

, thiazolidinediones and insulin. Whilst lifestyle support should be the primary approach to aid individuals who wish to lose weight, pharmacological approaches can also be considered. These include choosing glucose-lowering drugs or drug combinations that are weight neutral or result in weight loss or prescribing drugs that are specifically approved as anti-obesity medication. Given that some of the newer glucose-lowering medications that cause weight loss, such as glucagon-like peptide-1 receptor agonists (GLP-1 (...) RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), are also being used or considered for use as anti-obesity drugs, it seems that the distinction between glucose-lowering medication and weight loss medication is becoming blurred. This review discusses the main pharmacological approaches that can be used to support weight loss in individuals with diabetes.

2018 Diabetologia

177. Medical Versus Surgical ICU Obese Patient Outcome: A Propensity-Matched Analysis to Resolve Clinical Trial Controversies. Full Text available with Trip Pro

Medical Versus Surgical ICU Obese Patient Outcome: A Propensity-Matched Analysis to Resolve Clinical Trial Controversies. To determine the short- and long-term mortality of obese ICU patients following medical as opposed to surgical admission and the relation between obesity and mortality.Retrospective analysis of prospectively collected data, using a propensity score-matched analysis of patients with medical or surgical admission.One French mixed medical-surgical ICU.Critically ill obese (...) patients (body mass index ≥ 30 kg/m) and nonobese patients admitted during a 14-year period.None.Seven-hundred ninety-one obese patients and 4,644 nonobese patients were included, 338 (43%) and 2,367 (51%) medical and 453 (57%) and 2,277 (49%) surgical obese and nonobese patients, respectively. Mortality was significantly higher in medical than in surgical obese patients in ICU (25% vs 12%; p < 0.001) and up to 365 days (36% vs 18%; p < 0.001) post ICU admission. One-to-one propensity score matching

2018 Critical Care Medicine

178. Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial. (Abstract)

Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial. Enoxaparin dosing recommendations for morbidly obese patients are lacking. Retrospective and observational studies reported goal anti-Xa levels with a median dose of 0.8 mg/kg using total body weight. Further studies are needed to determine if a more conservative dosing strategy is warranted.To determine if reduced dose enoxaparin was more effective than (...) standard dose at achieving goal anti-Xa levels in morbidly obese patients.A prospective, randomized, controlled study was conducted in patients with a body mass index (BMI) ≥40 kg/m2. Patients were randomized to standard (1 mg/kg) or reduced dose (0.8 mg/kg) enoxaparin every 12 hours. The primary outcome was the proportion of patients with an initial anti-Xa at goal (0.5-1.1 IU/mL).A total of 62 patients were enrolled and randomized to 1 mg/kg (n = 32) or 0.8 mg/kg (n = 30), and 54 patients completed

2018 The Annals of pharmacotherapy Controlled trial quality: uncertain

179. Safety and tolerability of new-generation anti-obesity medications: a narrative review Full Text available with Trip Pro

Safety and tolerability of new-generation anti-obesity medications: a narrative review The prevalence of obesity and associated comorbidities is rising. Despite their weight-loss efficacy, new generation anti-obesity medications are only prescribed to a minority of adults with obesity, possibly, which in part may be due to safety concerns. This review presents detailed safety profiles for orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion and liraglutide 3.0 mg, and discusses (...) the associated risk-benefit profiles. Two anti-obesity medications presented safety issues that warranted further discussion; phentermine/topiramate (fetal toxicity) and liraglutide 3.0 mg (risk of gallstone disease and mild, acute pancreatitis), whereas the adverse events associated with orlistat, lorcaserin, and naltrexone/bupropion were mostly transient tolerability issues. The difficulties surrounding the objective determination of risk-benefit for anti-obesity medications is discussed. The need for more

2018 Postgraduate medicine

180. Asthma medication use in obese and healthy weight asthma: a systematic review and meta-analysis

Asthma medication use in obese and healthy weight asthma: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>